Intralesion and CuradermBEC5 Topical Combination Therapies of Solasodine Rhamnosyl Glycosides Derived from the Eggplant or Devil’s Apple Result in Rapid Removal of Large Skin Cancers. Methods of Treatment Compared
Bill E. Cham
“Villa Del Aripo”, Sheldon, Australia..
DOI: 10.4236/ijcm.2012.32024   PDF    HTML   XML   6,280 Downloads   12,031 Views   Citations


Solasodine rhamnosyl glycosides (SRGs) are chemotherapeutic agents for the treatment of cancer. SRGs in a cream formulation, CuradermBEC5, is very effective for the treatment of nonmelanoma skin cancers with excellent cosmetic end results. Intralesion injection of SRGs successfully dispose of very large tumours in animals without any clinical adverse effects. The mode of action of SRGs is by apoptosis. In this study, it is shown that small to large basal cell carcinomas are effectively treated only with topical application of CuradermBEC5. Here it is reported for the first time that combination of intralesion SRG injection and topical application with CuradermBEC5 in humans reduces the treatment time period by more than half when compared with topical application as the sole treatment regime. Two intralesion injections of very low doses of SRGs rapidly and effectively remove a large melanoma on a horse. If rapid removal of large troublesome skin cancers is required then this can be achieved by intralesion and topical treatments. Intralesion or combination therapy with SRGs may have some applications for melanomas in situ such as lentigo maligna.

Share and Cite:

B. E. Cham, "Intralesion and CuradermBEC5 Topical Combination Therapies of Solasodine Rhamnosyl Glycosides Derived from the Eggplant or Devil’s Apple Result in Rapid Removal of Large Skin Cancers. Methods of Treatment Compared," International Journal of Clinical Medicine, Vol. 3 No. 2, 2012, pp. 115-124. doi: 10.4236/ijcm.2012.32024.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] T. R. Chase, “Curaderm BEC5 for Skin Cancers, Is It? An Overview,” Journal Cancer Therapy, Vol. 2, No. 5, 2011, pp. 728-745. doi:10.4236/jct.2011.25099
[2] B. E. Cham, “Eggplant Wins War against Skin Cancer. Conquest on the Horizon for Internal Cancers?” in Preparation.
[3] B. E. Cham, “The Eggplant Cancer Cure. A Treatment for Skin Cancer and New Hope for Other Cancers from Nature’s Pharmacy,” Smart Publications, Petaluma, 2007, p. 122.
[4] B. E. Cham, M. Gilliver and L. Wilson, “Antitumour Effects of Glycoalkaloids Isolated from Solanum sodomaeum L.,” Planta Medica, Vol. 53, No. 1, 1987, pp. 34-36. doi:10.1055/s-2006-962612
[5] B. E. Cham and B. Daunter, “Solasodine Glycosides. Selective Cytoxicity for Cancer Cells and Inhibition of Cytotoxicity by Rhamnose in Mice with Sarcoma 180,” Cancer Letters, Vol. 55, No. 3, 1990, pp. 221-225. doi:10.1016/0304-3835(90)90122-E
[6] M. Freedman, K. R. Lee, H. J. Kim, I. S. Lee and N. Kozukue, “Anticarcinogenic Effects of Glycoalkaloids from Potatoes against Human Cervical, Liver, Lymphoma and Stomach Cancer Cells,” Journal Agriculture Food Chemistry, Vol. 53, No. 15, 2005, pp. 6162-6169. doi:10.1021/jf050620p
[7] K. W. Kuo, S. H. Hsu, Y. P. Li, W. L. Lin, L. F. Liu, L. C. Chang, C. C. Lin, C. N. Lin and H. M. Sheu, “Anticancer Activity Evaluation of the Solanum Glycoalkaloid Solamargine. Triggering Apoptosis in Human Hepatoma Cells,” Biochemistry Pharmacology, Vol. 60, No. 2, 2000, pp. 1865-1873. doi:10.1016/S0006-2952(00)00506-2
[8] K.W. Kuo and C. N. Lin, “Pharmacological Composition for Treating Cancer Cells,” United States Patent 6, 214, 803, 1999.
[9] K. R. Lee, N. Kozukue, J. S. Han, J. H. Park, E. Y. Chang, E. J. Back, J. S. Chang and M. Friedman, “Glycoalkaloids and Metabolites Inhibit the Growth of Human Colon (HT29) and Liver (HepG2) Cancer Cells,” Journal Agriculture Food Chemistry, Vol. 52, No. 10, 2004, pp. 2832-2839. doi:10.1021/jf030526d
[10] C. H. Liang, L. F. Liu, L. Y. Shiu, Y. S. Huang, L. C. Chang and K. W. Kuo, “Action of Solamargine on TNFs and Cisplatin-Resistant Human Lung Cancer Cells,” Biochemistry Biophysics Research Communication, Vol. 322, No. 3, 2004, pp. 751-758. doi:10.1016/j.bbrc.2004.07.183
[11] C. H. Liang, L. Y. Shiu, L. C. Chang, H. M. Sheu and K. W. Kuo, “Solamargine Upregulation of Fas, Downregulation of HER 2, and Enhancement of Cytotoxicity Using Epirubicin in NSCLC Cells,” Molecular Nutrition Food Research, Vol. 51, No. 8, 2007, pp. 999-1005. doi:10.1002/mnfr.200700044
[12] L. F. Liu, C. H. Liang, L. Y. Shiu, W. L. Lin, C. C. Lin and K. W. Kuo, “Action of Solamargine on Human Lung Cancer Cells-Enhancement of the Susceptibility of Cancer Cells to TNFs.,” FEBS Letters, Vol. 577, No. 1-2, 2004, pp. 67-74. doi:10.1016/j.febslet.2004.09.064
[13] M. Millward, A. Powell, P. Daly, S. Tyson, R. Ferguson and S. Carter, “Results of Phase I Clinical Trials of Coramsine in Patients with Advanced Solid Tumors,” Journal Clinical Oncology, Vol. 2, No. 18, 2006, p. 2070.
[14] T. Nakamura, C. Komori, Y. Lee, F. Hashinoto, S. Yahara, T. Nohara and A. Ejina, “Cytotoxic Activities of Solanum Steroidal Glycosides,” Biological Biopharmacology Bulletin, Vol. 19, No. 4, 1996, pp. 564-566. doi:10.1248/bpb.19.564
[15] K. Ono, S.O. Kin and J.Han, “Susceptibility of Lysosomes To Rupture Is a Determinant for Plasma Membrane Disruption in Tumor Necrosis Factor Alpha-Induced Cell Death,” Molecular Cell Biology, Vol. 23, No. 2, 2003, pp. 665-676. doi:10.1128/MCB.23.2.665-676.2003
[16] M. Ono, K. Nishimura, K. Suzuki, T. Fukushima, K. Igoshi, H. Yoshimitsu, T. Ikeda and T. Nohara, “Steroidal Glycosides from the Underground Parts of Solanum Sodomaeum,” Chemistry Pharmacology Bulletin, Vol. 54, No. 2, 2006, pp. 230-233. doi:10.1248/cpb.54.230
[17] J. G. Roddick, A. L. Ryrenber and M. Weissenber, “Membrane-Disrupting Properties of the Steroidal Glycoalkaloids Solasonine and Solamargine,” Phyto Chemistry, Vol. 29, No. 5, 1990, pp. 1513-1518. doi:10.1016/0031-9422(90)80111-S
[18] P. Vijayan, K. S. Vinod, S. A. Dhanaraj, S. Badami and B. Suresh, “In Vitro Cytotoxicity and Anti-Tumour Properties of the Total Alkaloid Fraction of Unripe Fruits of Solanum pseudocapsicum,” Pharmaceutical Biology, Vol. 40, No. 6, 2002, pp. 456-460. doi:10.1076/phbi.40.6.456.8444
[19] B. E. Cham, “Solasodine Rhamnosyl Glycosides Specifically Bind Cancer Cell Receptors and Induce Apoptosis and Necrosis. Treatment for Skin Cancer and Hope for Internal Cancers,” Research Journal Biological Sciences, Vol. 2, No. 7, 2007, pp. 503-514.
[20] B. E. Cham, “Solasodine Rhamnosyl Glycosides in a Cream Formulation Is Effective for Treating Large and Troublesome Skin Cancers,” Research Journal Biological Sciences, Vol. 2, No. 7, 2007, pp. 749-761.
[21] B. E. Cham, “Cancer Intralesion Chemotherapy with Solasodine Rhamnosyl Glycosides,” Research Journal Biological Sciences, Vol. 3, 2008, pp. 1008-1017.
[22] L. Y. Shiu, L. C. Chang, C. H. Liang, Y. S. Huang, H. M. Sheu and K. W. Kuo, “Solamargine Induces Apoptosis and Sensitizes Breast Cancer Cells to Cisplatin,” Food Chemistry Toxicology, Vol. 45, No. 11, 2007, pp. 2155-2164. doi:10.1016/j.fct.2007.05.009
[23] Solamargine anticancer. Google Search
[24] B. E. Cham and T. R. Chase, “Solasodine Rhamnosyl Glycosides Cause Apoptosis in Cancer Cells, Do They also Prime the Immune System Resulting in Long Term Protection against Cancer?” Planta Medica, Vol. 78, 2012, pp. 349-353. doi:10.1055/s-0031-1298149
[25] R. G. Van der Most, R. Himbeck, S. Aarens, S. J. Carter, I. Larma, C. Robinson, A. Currice and R. A. Lake, “Antitumor Efficacy of the Novel Chemotherapeutic Agent Coramsine Is Potentiated by Cotreatment with CpG-Containing Oligodeoxynucleotides,” Journal Immunotherapy, Vol. 29, No. 2, 2006, pp. 134-142. doi:10.1097/01.cji.0000187958.38179.a9
[26] B. Daunter and B. E. Cham, “Solasodine Glycosides. In Vitro Preferential Cytotoxicity for Human Cancer Cells,” Cancer Letters, Vol. 55, No. 3, 1990, pp. 209-220. doi:10.1016/0304-3835(90)90121-D
[27] X. Li, Y. Zhao, W. K. K. Wu, S. Liu, M. Cui and H. Lou, “Solamargine Induces Apoptosis Associated with p53 Transcription-Dependent and Transcription-Independent Pathways in Human Osteosarcoma U20S Cells,” Life Science, Vol. 88, No. 7-8, 2011, pp. 314-321. doi:10.1016/j.lfs.2010.12.006
[28] B. E. Cham, “Monograph on the Compound BEC,” Drugs of the Future, Vol. 13, 1988, pp. 714-716.
[29] B .E. Cham, “Solasodine Glycosides as Anti-Cancer Agents: Pre-Clinical and Clinical Studies,” Asia Pacific Journal Pharmacology, Vol. 9, No. 2, 1994, pp. 113-118.
[30] L. Y. Shiu, C. H. Liang, Y. S. Huang, H. M. Sheu and K. W. Kuo, “Downregulation of HER2/neu Receptor by Solamargine Enhances Anticancer Drug-Mediated Cytotoxicity in Breast Cancer Cells with High-Expressing HER2/neu,” Cellular Biology Toxicology, Vol. 24, No. 1, 2008, pp. 1-10. doi:10.1007/s10565-007-9010-5
[31] C. Paquet, A. T. Sané, M. Beauchemin and R. Bertrand, “Caspase- and Mitochondrial Dysfunction Dependent Mechanisms of Lysosomal Leakage and Cathepsin B Activation in DNA Damage-Induced Apoptosis,” Leukemia, Vol. 19, No. 5, 2005, pp. 784-791. doi:10.1038/sj.leu.2403717
[32] L. Sun, Y. Zhao, H. Yuan, X. Li, A. Cheng and H. Lou, “Solamargine, a Steroidal Alkaloid Glycoside, Induces Oncosis in Human K562 Leukemia and Squamous Cell Carcinoma KB Cells,” Cancer Chemotherapy Pharmacol, Vol. 65, No. 4, 2010, pp. 1125-1130.
[33] B. E. Cham and B. Daunter, “Topical Treatment of Pre-Malignant and Malignant Skin Cancers with Curaderm,” Drugs of Today, Vol. 26, No. 3, 1990, pp. 55-58.
[34] B. E. Cham, B. Daunter and R. Evans, “Topical Treatment of Malignant and Premalignant Skin Cancers by Very Low Concentrations of a Standard Mixture of Solasodine Glycosides,” Cancer Letters, Vol. 59, No. 3, 1991, pp. 183-192. doi:10.1016/0304-3835(91)90140-D
[35] B. E. Cham and M. M. Meares, “Glycoalkaloids from Solanum sodomaeum L. Are Effective in the Treatment of Skin Cancers in Man,” Cancer Letters, Vol. 36, No. 2, 1987, pp. 111-118. doi:10.1016/0304-3835(87)90081-4
[36] S. Punjabi, I. Cook, P. Kersey, R. Marks, A. Finlay and G. Sharpe, “A Double Blind, Multi-Centre Parallel Group Study of BEC-5 Cream in Basal Cell Carcinoma,” European Academy Dermatology Venereology, Vol. 14, 2000, pp. 47-60.
[37] S. Punjabi, L. J. Cook, P. Kersey, R. Marks and R. Cerio, “Solasodine Glycoalkaloids: A Novel Topical Therapy for Basal Cell Carcinoma. A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicentre Study,” International Journal Dermatology, Vol. 47, No. 1, 2008, pp. 78-82. doi:10.1111/j.1365-4632.2007.03363.x
[38] H. W. Rogers, N. A. Weinstock, A. R. Harris, M. R. Hinckley, S. R. Feldman, A. B. Fleischer and B. M. Coldiron, “Incidence Estimate of Nonmelanoma Skin Cancer in the United States,” Archives Dermatology, Vol. 146, No. 3, 2010, pp. 283-287. doi:10.1001/archdermatol.2010.19
[39] M. B. Lens and M. Dawes, “Epidemiological Trends of Cutaneous Malignant Melanoma: Incidence of Cutaneous Malignant Melanoma,” British Journal of Dermatology, Vol. 150, No. 2, 2004, pp. 179-185. doi:10.1111/j.1365-2133.2004.05708.x
[40] L. A. E. Sussman and D. F. Liggins, “Incompletely Excised Basal Cell Carcinoma a Management Dilemma?” Australia New Zealand Journal Surgery, Vol. 66, No. 5, 1996, pp. 276-278. doi:10.1111/j.1445-2197.1996.tb01184.x
[41] B. E. Cham, “Topical Solasodine Rhamnosyl Glycosides Derived from the Eggplant Treats Large Skin Cancers: Two Case Reports,” International Journal Clinical Medicine, Vol. 2, No. 4, 2011, pp. 473-477. doi:10.4236/ijcm.2011.24080
[42] B. E. Cham and L. Wilson, “HPLC of Glycoalkaloids from Solanum sodomaeum,” Planta Medica, Vol. 53, No. 1, 1987, pp. 34-36. doi:10.1055/s-2006-962612
[43] L. H. Goldberg, J. M. Landau, M. N. Moody and I. J. Vergilis-Kalner, “Treatment of Bowen’s Disease on the Penis with Low Concentration of a Standard Mixture of Solasodine Glycosides and Liquid Nitrogen,” Dermatologic Surgery, Vol. 37, No. 6, 2011, pp. 858-861. doi:10.1111/j.1524-4725.2011.02014.x

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.